Promega and BASF Develop Alternative Method on Identifying Allergenic Substances
News Apr 11, 2013
Promega and BASF have jointly developed an alternative method to animal studies that can reliably detect the allergenic potential of substances. Using a newly developed cell line, the reaction of skin cells to allergenic substances can now be demonstrated in the test tube.
Allergic skin reactions involve a variety of biochemical processes. These include the binding of a substance to one of the skin’s proteins and a resulting stress reaction. Both are early and reliable indicators of a possible allergenic potential of the test substance. In the newly developed cell line, scientists of RWTH Aachen University Hospital have modified a reporter gene from Promega, so that the stress reactions are coupled to a light signal. This gene construct was then stably inserted into human skin cell lines. Dr. Katarina Bohm, Marketing Manager of Promega: “Our luciferase vectors translate cellular changes into a luminescent signal. This allows stress reactions in skin cells to be easily detected with our luciferase assay systems.” The new cell line has been extensively tested at BASF and a standardized method has been developed to reliably assess the allergenic potential of a substance.
Previously, the skin sensitizing action of substances had to be determined in animal studies. “Combining the new method with two additional alternative methods to investigate skin sensitization allows us not only to significantly reduce the number of animal studies, but also to predict a possible allergic potential more reliably than before,” said Dr. Robert Landsiedel, Head of the short-term Toxicology unit at BASF. Developing the method at the present time is particularly important because following the REACH regulation, several thousand substances have to be tested for their skin sensitizing action by 2018. Furthermore, since March 2013 animal studies on cosmetic ingredients for the European market have been completely prohibited.
The alternative method was submitted to the European Commission (European Center for the Validation of Alternative Methods, ECVAM). This body determines whether it can be recognized as a standard method for toxicological studies in Europe.
CRISPR Reveals New Targets for Promising Cancer DrugsNews
Novel screening method identifies new drug targets that could potentially enhance the effectiveness of PD-1 checkpoint inhibitors, a promising new class of cancer immunotherapy.READ MORE
Cell Recycling System Offers Therapeutic Entry Point for Rare Disease TreatmentNews
Scientists have demonstrated how an investigational drug works against a rare, fatal genetic disease, Niemann-Pick type C1 (NPC1).READ MORE
Cancer Cells Force Normal Cells to Act Like Viruses, Helping Tumors SpreadNews
Researchers reveal how cancer cells force normal cells to act like viruses – allowing tumors to grow, resist treatment, and spread.READ MORE
Comments | 0 ADD COMMENT
EMBL Conference: European Conference of Life Science Funders and Foundations
Apr 19 - Apr 20, 2018
EMBL Course: Target Engagement in Biology and Drug Discovery
Feb 19 - Feb 23, 2018